-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On December 5th, Junshi Biopharmaceuticals issued an announcement announcing that the FDA has expanded the emergency use authorization scope of Etesevimab (etesevimab, JS016) and Banivirimab (bamlanivimab, LY-CoV555) dual-antibody therapy, adding Treatment and post-exposure prevention for mild to moderate new coronavirus pneumonia in selected high-risk pediatric populations (from birth to under 12 years old)
In February 2021, diabody therapy has been authorized by the FDA for emergency use to treat patients with mild to moderate COVID-19 who are at risk of progression to severe COVID-19 and/or hospitalization
This expanded emergency use authorization is based on the safety and effectiveness data of pediatric and infant patients in the BLAZE-1 study (NCT04427501)
It is worth noting that the studies of pseudoviruses and true viruses have shown that the double antibody therapy maintains neutralizing activity in the delta mutant test against the current mainstream mutant strain of global attention
